QPPV.COM KNOWLEDGE ASSESSMENT

Signal Validation in Pharmacovigilance

Test your understanding of the concepts covered by Signal Validation in Pharmacovigilance.

Question 1 of 10Pass mark: 80%

Question 1 of 10 What is the most appropriate interpretation of a positive dechallenge during signal validation?

It is evidence that may support the association, but it does not by itself establish causality It is irrelevant unless a positive rechallenge also occurred It conclusively proves the product caused the event It automatically requires immediate product withdrawal

Question 2 of 10 Which action is most appropriate after a signal has been deferred?

Remove it from the tracking register because no decision was made Specify the required evidence, assign responsibility and set a due date for reassessment Treat it as equivalent to a final not-validated decision Wait indefinitely for unsolicited information

Question 3 of 10 Which sequence best represents the signal management model described in the article?

Detection, assessment, triage, validation, closure, recommendation Detection, triage, validation, assessment, recommendation, action or closure Triage, detection, validation, recommendation, assessment, closure Detection, validation, action, assessment, triage, recommendation

Question 4 of 10 Which approach best reflects the article's position on validation criteria?

Use a single numerical threshold as the universal determinant Apply a structured, multidimensional review adapted into SOPs and templates Rely exclusively on the seriousness of the event Use only biological plausibility and ignore case quality

Question 5 of 10 A database alert is generated because of duplicate coding records that represent the same underlying case. What is the most appropriate initial process response?

Escalate immediately to the QPPV as a validated signal Begin a full benefit-risk assessment Address the issue during triage as a technical artefact Close the product's signal management process

Question 6 of 10 A signal reviewer identifies a possible new serious risk but has reviewed only summary counts, not the underlying case narratives. What is the most appropriate next step?

Finalize validation solely from the summary counts Retrieve and review primary sources such as ICSR narratives and relevant clinical data Discard the observation because summary data are never useful Escalate it as confirmed causality

Question 7 of 10 Which missing information most directly weakens evaluation of temporal plausibility?

The reviewer's professional title The product's packaging design The dates of exposure and event onset The number of pages in the signal dossier

Question 8 of 10 Which statement best distinguishes signal validation from causality assessment?

Validation determines whether further structured evaluation is justified, whereas causality assessment evaluates the relationship in greater depth Validation is quantitative only, whereas causality assessment is qualitative only Validation is performed by regulators, whereas causality assessment is performed by marketing authorisation holders Validation applies only to spontaneous reports, whereas causality assessment applies to all sources

Question 9 of 10 Why should validation take place promptly after detection?

To ensure that every detected observation becomes a validated signal To preserve timely risk identification and prevent accumulation of a validation backlog To avoid the need to document the evidence reviewed To ensure that statistical thresholds alone determine the outcome

Question 10 of 10 Which conclusion is most scientifically appropriate when an observation is validated?

The product-event relationship has been conclusively proven The event must immediately be added to the product information The evidence is sufficient to justify formal signal assessment, without necessarily proving causality No further data collection is needed

Signal Validation in Pharmacovigilance

Cookie Settings